---

$1.21

-0.0050 ( -0.41% ) 647.1K

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-11-26	Buy	15000.00	Howe Jill Ann
2024-11-26	Buy	15000.00	Samuel George A. III
2024-11-25	Buy	40000.00	Mulroy Michael H.
2024-11-22	Buy	40000.00	Culley Brian M
2024-08-19	Buy	10500.00	Howe Jill Ann
2024-07-03	Sale	-75000.00	Amin Dipti
2024-07-03	Sale	-75000.00	BRADSHER NEAL C
2024-07-03	Sale	-75000.00	BAILEY DON M
2024-07-03	Sale	-75000.00	Russell Angus C.
2024-07-03	Sale	-75000.00	Mulroy Michael H.